The firm uses its innovative TransCon technologies to address unmet medical needs.

In September 2020, Ascendis announced positive preliminary six-month results from the open-label extension portion of PaTH Forward, a global Phase II trial evaluating the safety, tolerability and efficacy of TransCon PTH in adult subjects with hypoparathyroidism.

EvaluatePharma’s sell-side consensus sees Transcon PTH generating $847 million of 2026 sales.